Tyra Biosciences (TYRA) director Dable Habib J files Form 3 showing no share ownership

Rhea-AI Filing Summary

Tyra Biosciences, Inc. director Dable Habib J filed an initial Form 3 reporting his ownership position in the company. The filing states that no securities are beneficially owned, meaning he reports holding zero Tyra Biosciences shares at this time.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Dable Habib J

Role null

Type	Security	Shares	Price	Value
holding	No securities are beneficially owned.	--	--	--

Holdings After Transaction: No securities are beneficially owned. — 0 shares (Direct, null)

Footnotes (1)

Key Figures

Beneficial ownership: 0 shares

1 metrics

Beneficial ownership 0 shares Total shares beneficially owned following reported entry

Key Terms

beneficially owned, reporting person, Form 3

3 terms

beneficially owned financial

"No securities are beneficially owned."

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

reporting person regulatory

"The reporting person is identified as Dable Habib J."

Form 3 regulatory

"Initial statement of beneficial ownership on Form 3."

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

Understanding Insider Trading Forms →

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Dable Habib J

(Last) (First) (Middle)

C/O TYRA BIOSCIENCES, INC.

2656 STATE STREET

(Street)

CARLSBAD CALIFORNIA 92008

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
04/16/2026

3. Issuer Name and Ticker or Trading Symbol
Tyra Biosciences, Inc. [ TYRA ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
No securities are beneficially owned.	0	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Exhibit 24 - Power of Attorney

	/s/ Ali D. Fawaz, Attorney-in-Fact	04/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does the Tyra Biosciences (TYRA) Form 3 for Dable Habib J show?

The Form 3 for Tyra Biosciences director Dable Habib J reports that he beneficially owns no securities of the company. This initial filing simply establishes his starting ownership position as zero shares.

Did Dable Habib J buy or sell any TYRA shares in this Form 3 filing?

No buy or sell transactions are reported in this Form 3. It only shows a holding entry stating that no securities are beneficially owned, so there are no reported share purchases, sales, or option exercises.

What is the purpose of this Tyra Biosciences (TYRA) Form 3 filing?

This Form 3 serves as an initial statement of beneficial ownership for director Dable Habib J. It discloses his starting position in Tyra Biosciences, which the filing states is zero shares beneficially owned.

How many Tyra Biosciences (TYRA) shares does Dable Habib J report owning?

The filing reports a total of 0 shares beneficially owned following the reported entry. The security title field specifically notes that no securities are beneficially owned by the reporting person at this time.

Does this Tyra Biosciences (TYRA) Form 3 include any derivative securities?

No derivative positions are shown in this Form 3. The derivative summary is empty, and the only reported entry states that no securities are beneficially owned, covering both common and derivative securities.